FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602173458> ?p ?o ?g. }

• W2602173458 abstract "156 Background: The outcomes of pts receiving first-line CT vs AT for mCRPC are unclear. Using the VHA dataset, we compared outcomes with first-line CT vs AT in pts with mCRPC and assessed the impact of prior androgen deprivation therapy (ADT) duration and known prognostic factors. Methods: Pts with mCRPC initiating first-line AT (abiraterone, enzalutamide) or CT (taxane) from Oct 2012 to Sept 2014 were identified. The impact of AT vs CT on overall survival (OS) and time to discontinuation (TTD) was assessed using Cox proportional hazard models, adjusting for prior ADT duration, known prognostic factors (hemoglobin [Hb], albumin [alb], alkaline phosphatase [ALP], prostate-specific antigen [PSA]), Charlson Comorbidity Index (CCI) and chronic disease score (CDS). Results: Overall, 1445 pts were evaluable; 1108 received AT (abiraterone 996, enzalutamide 112) and 337 received CT (docetaxel). The overall median duration of prior ADT was 464 days. On multivariable analysis, prior ADT duration, CCI, CDS, Hb, Alb, ALP and PSA were associated with OS, but AT vs CT was not (HR: 1.041 [95% CI: 0.853–1.270], p = 0.6943). PSA levels, prior ADT duration, and ALP was associated with TTD, and TTD was shorter for CT vs AT (HR: 2.339 [95% CI: 1.969–2.779], p < 0.0001). Longer prior ADT duration was associated with longer OS (HR: 0.566, p < 0.0001) and TTD (HR: 0.831, p = 0.0363) in the AT cohort, but not in the CT cohort. Treatment-free interval (TFI) (between first- and second-line treatment) was longer for CT vs AT (mean: 53 vs 39 days; p = 0.0303). Conclusions: To our knowledge, this is one of the largest mCRPC datasets analyzed at the individual pt level comparing first-line CT vs AT. OS was not significantly different for first-line CT vs AT after adjusting for key prognostic factors, despite shorter TTD with CT and longer TFI after first-line CT. Prior ADT duration ≤ 464 days was associated with shorter OS and TTD in the AT cohort, but not the CT cohort, suggesting that such pts may benefit from receiving CT over AT. The results are hypothesis-generating and prospective validation is required. Funding: Sanofi Genzyme" @default.
• W2602173458 created "2017-04-07" @default.
• W2602173458 creator A5012278873 @default.
• W2602173458 creator A5038329313 @default.
• W2602173458 creator A5048953246 @default.
• W2602173458 creator A5052069729 @default.
• W2602173458 creator A5064447813 @default.
• W2602173458 date "2017-02-20" @default.
• W2602173458 modified "2023-09-22" @default.
• W2602173458 title "First-line chemotherapy (CT) versus anti-androgen therapy (AT) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Individual patient analysis of the Veterans Health Administration (VHA) dataset." @default.
• W2602173458 doi "https://doi.org/10.1200/jco.2017.35.6_suppl.156" @default.
• W2602173458 hasPublicationYear "2017" @default.
• W2602173458 type Work @default.
• W2602173458 sameAs 2602173458 @default.
• W2602173458 citedByCount "1" @default.
• W2602173458 countsByYear W26021734582020 @default.
• W2602173458 crossrefType "journal-article" @default.
• W2602173458 hasAuthorship W2602173458A5012278873 @default.
• W2602173458 hasAuthorship W2602173458A5038329313 @default.
• W2602173458 hasAuthorship W2602173458A5048953246 @default.
• W2602173458 hasAuthorship W2602173458A5052069729 @default.
• W2602173458 hasAuthorship W2602173458A5064447813 @default.
• W2602173458 hasConcept C121608353 @default.
• W2602173458 hasConcept C126322002 @default.
• W2602173458 hasConcept C143998085 @default.
• W2602173458 hasConcept C2776694085 @default.
• W2602173458 hasConcept C2777899217 @default.
• W2602173458 hasConcept C2780192828 @default.
• W2602173458 hasConcept C2993493390 @default.
• W2602173458 hasConcept C71924100 @default.
• W2602173458 hasConceptScore W2602173458C121608353 @default.
• W2602173458 hasConceptScore W2602173458C126322002 @default.
• W2602173458 hasConceptScore W2602173458C143998085 @default.
• W2602173458 hasConceptScore W2602173458C2776694085 @default.
• W2602173458 hasConceptScore W2602173458C2777899217 @default.
• W2602173458 hasConceptScore W2602173458C2780192828 @default.
• W2602173458 hasConceptScore W2602173458C2993493390 @default.
• W2602173458 hasConceptScore W2602173458C71924100 @default.
• W2602173458 hasLocation W26021734581 @default.
• W2602173458 hasOpenAccess W2602173458 @default.
• W2602173458 hasPrimaryLocation W26021734581 @default.
• W2602173458 hasRelatedWork W2245991325 @default.
• W2602173458 hasRelatedWork W2587031275 @default.
• W2602173458 hasRelatedWork W2587196322 @default.
• W2602173458 hasRelatedWork W2588167612 @default.
• W2602173458 hasRelatedWork W2589688070 @default.
• W2602173458 hasRelatedWork W2590423905 @default.
• W2602173458 hasRelatedWork W2595859672 @default.
• W2602173458 hasRelatedWork W2597207637 @default.
• W2602173458 hasRelatedWork W2598242756 @default.
• W2602173458 hasRelatedWork W2599725518 @default.
• W2602173458 hasRelatedWork W2600343577 @default.
• W2602173458 hasRelatedWork W2602660925 @default.
• W2602173458 hasRelatedWork W2767440403 @default.
• W2602173458 hasRelatedWork W2792793494 @default.
• W2602173458 hasRelatedWork W2794350829 @default.
• W2602173458 hasRelatedWork W2794425503 @default.
• W2602173458 hasRelatedWork W2921492570 @default.
• W2602173458 hasRelatedWork W3092324143 @default.
• W2602173458 hasRelatedWork W3134553248 @default.
• W2602173458 hasRelatedWork W3179582685 @default.
• W2602173458 isParatext "false" @default.
• W2602173458 isRetracted "false" @default.
• W2602173458 magId "2602173458" @default.
• W2602173458 workType "article" @default.